All In Biotech

Drug Trial Radar · NCT03770403

A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness.

A Long-Term, Single-Arm, Open-Label, Multicenter, Phase 3 Follow-on Trial of ARGX-113-1704 to Evaluate the Safety and Tolerability of ARGX-113 in Patients With Myasthenia Gravis Having Generalized Muscle Weakness

Last checked: Nov 20, 2026Latest source record: Jul 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

151

Actual

Start

Mar 1, 2019

Primary completion

Jun 23, 2022

Study completion Jun 30, 2022

Sponsor

Lead sponsor
argenxargenx (ARGX)
Sponsor type
Industry
First posted
Dec 10, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Long-Term, Single-Arm, Open-Label, Multicenter Phase 3 follow-on trial of the ARGX-113-1704 study to evaluate the safety and tolerability of ARGX-113 in patients with gMG. Patients who have completed at least 1 cycle of treatment and at least 1 year of trial ARGX-113-1705 and have started Part B are eligible to enroll in the open-label trial ARGX-113-2002 to receive efgartigimod by SC administration.

Conditions

  • Generalized Myasthenia Gravis

Interventions

  • ARGX-113Biological

    Intravenous administration of ARGX-113

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious AEs, TEAEs Leading to Study Drug Discontinuation and Fatal TEAE in AChR-Positive ParticipantsTime frame: TEAEs were collected from the start of first administered study treatment (Day 1) up to end of follow-up, approximately up to 3 years

Locations

52 sites in 15 countries. Site status is shown where the registry gives one.

  • Investigator Site 42

    Carlsbad, California

  • Investigator Site 8

    Los Angeles, California

  • Investigator Site 33

    Orange, California

  • Investigator Site 21

    Palo Alto, California

  • Investigator Site 41

    Jacksonville, Florida

  • Investigator Site 4

    Tampa, Florida

  • Investigator Site 14

    Kansas City, Kansas

  • Investigator Site 32

    Detroit, Michigan

  • Investigator Site 2

    Chapel Hill, North Carolina

  • Investigator Site 18

    Cleveland, Ohio

  • Investigator Site 12

    Portland, Oregon

  • Investigator Site 1

    Cordova, Tennessee

  • Investigator Site 3

    San Antonio, Texas

  • Investigator Site 37

    Charlottesville, Virginia

  • Investigator Site 11

    Edegem, Belgium

  • Investigator Site 7

    Ghent, Belgium

  • Investigator Site 20

    Toronto, Ontario, Canada

  • Investigator Site 25

    Montreal, Quebec, Canada

  • Investigator Site 16

    Brno, Czechia

  • Investigator Site 19

    Ostrava-Poruba, Czechia

  • Investigator Site 30

    Prague, Czechia

  • Investigator Site 49

    Aarhus, Denmark

  • Investigator Site 17

    Copenhagen, Denmark

  • Investigator Site 50

    Bordeaux, France

  • Investigator Site 51

    Marseille, France

  • Investigator Site 45

    Tbilisi, Georgia

  • Investigator Site 31

    Tbilisi, Georgia

  • Investigator Site 46

    Tbilisi, Georgia

  • Investigator Site 28

    Berlin, Germany

  • Investigator Site 35

    Budapest, Hungary

  • Investigator Site 52

    Szeged, Hungary

  • Investigator Site 5

    Naples, Italy

  • Investigator Site 38

    Roma, Italy

  • Investigator Site 10

    Milan, MI, Italy

  • Investigator Site 47

    Chiba, Japan

  • Investigator Site 44

    Hiroshima, Japan

  • Investigator Site 48

    Minato, Japan

  • Investigator Site 24

    Sapporo, Hokkaido, Japan

  • Investigator Site 13

    Hanamaki-shi, Iwate, Japan

  • Investigator Site 27

    Sendai, Miyagi, Japan

Showing 40 of 52 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.